DNA methylation: An epigenetic process of medical importance;Metilación del ADN: Un fenómeno epigenético de importancia Médica

Revista de Investigacion Clinica

Volumn 56, Issue 1, 2004, Pages 56-71

  Rodríguez Dorantes, Mauricio ^a   Téllez Ascencio, Nelly ^a   Cerbón, Marco A ^a   Lez, Marisol ^b   Cervantes, Alicia ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Cancer; DNA methylation; Epigenetics; Genomic imprinting; Histone modifications

Indexed keywords

DNA METHYLTRANSFERASE; METHYL CPG BINDING PROTEIN;

BECKWITH WIEDEMANN SYNDROME; CARCINOGENESIS; CPG ISLAND; DEVELOPMENTAL DISORDER; DNA METHYLATION; EPIGENETICS; FRAGILE X SYNDROME; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENOME IMPRINTING; HUMAN; PRADER WILLI SYNDROME; REGULATORY MECHANISM; RETT SYNDROME; REVIEW; TRANSCRIPTION REGULATION; X CHROMOSOME INACTIVATION;

ANIMALS; CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC DISEASES, INBORN; GENOME; MAMMALS; NEOPLASMS; TRANSCRIPTION, GENETIC; X CHROMOSOME;

EID: 2342621426     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291: 1304-51.
2. International Human Genome Sequencing Consortium. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
3. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 1999; 286: 481-6.
4. Nakao M. Epigenetics: interaction of DNA methylation and chromatin. Gene 2001; 278: 25-31.
5. Brown TA. Genomes. 2nd. Ed. U.K.: Wiley-Liss Manchester; 2002, p. 572.
6. Lyko F, Ramsahoye BH, Jaenisch R. DNA methylation in Drosophila melanogaster. Nature 2000; 408: 538-40.
7. Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird AP, Jaenisch R. None-CpG methylation is prevalent in embryonic stem cells and maybe mediated by DNA methyltransferase 3a. Proc Natl Acad Sci USA 2000; 97: 5237-42.
8. Costello JF, Plass C. Methylation matters. J Med Genet 2001; 38: 285-303.
9. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21.
10. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA 1993; 90:11995-9.
11. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, Tempst P, Reinberg D, Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 1999; 23: 58-61.
12. Bird AP, Taggart MH, Nicholls RD, Higgs DR. None-methylated CpG-rich islands at the human a globin locus: implications for evolution of the a globin pseudogene. EMBO J 1987; 6: 999-1004.
13. McKeon C, Ohkubo H, Pastan I, de Crombrugghe B. Unusual methylation pattern of the a 2(1) collagen gene. Cell 1982; 29: 203-10.
14. Kafri T, Ariel M, Brandeis M, Shemer R, Urven L, McCarrey J, Cedar H, Razin A. Developmental pattern of gene-specific DNA methylation in the mouse embryo and germ line. Genes Dev 1992; 6: 705-14.
15. Paulsen M, Ferguson-Smith AC. DNA methylation in genomic imprinting, development, and disease. J Pathol 2001; 195: 97-110.
16. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science 2001; 293: 1089-93.
17. Bird A, Wolffe AP. Methylation induces repression-belts, braces and chromatin. Cell 1999; 99: 451-4.
18. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000; 9: 2395-402.
19. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69: 915-26.
20. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for the novo methylation and mammalian development. Cell 1999; 99: 247-57.
21. Doerfler W. DNA methylation and gene activity. Annu Rev Biochem 1983; 52: 93-124.
22. Araujo FD, Knox JD, Szyf M, Price GB. Zannis-Hadjopoulos M. Concurrent replication and methylation at mammalian origins of replication. Mol Cell Biol 1998; 18: 3475-82.
23. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 1997; 277: 1996-2000.
24. Burgers WA, Fuks F, Kouzarides T. DNA methyltransferases get connected to chromatin Trends Genet 2002; 18: 275-7.
25. Xu GL, Bestor TH, Bourc'his D, Hsieh L, Tommerup N, Bugge M. Hulten M, Ku X, Russo JJ, Viegas-Pequignot E. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402: 187-91.
26. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 y HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000; 25: 338-42.
27. Bachman KE, Rountree MR, Baylin SB. Dnmt3a y Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem 2001; 276: 32282-7.
28. Cervoni N, Bhattacharya S, Szyf M. DNA demethylase is a processive enzyme. J Biol Chem 1999; 274: 8363-6.
29. Wolffe AP, Jones PL, Wade PA. DNA demethylation. Proc Natl Acad Sci USA 1999; 96: 5894-6.
30. Kress C, Thomassin H, Grange T. Local DNA demethylation in vertebrates: how could it be performed and targeted? FEBS Let 2001; 494: 135-40.
31. Zhu B, Zheng Y, Hess Angliker H, Schwarz S, Siegmann M, Thiry S. Jost JP. %-Methylcytosine DNA glycosylase activity is present in a cloned G/T mismatch glycosilase associated with the chiken embryo DNA demethylation complex. Proc Natl Acad Sci USA 2000; 97: 5135-39.
32. Oswald J, Engemann S, Lane E, Mayer W, Olek A, Fundele R, Dean W, Reik W, Walter J. Active demethylation of the paternal genome in the mouse zygote. Curr Biol 2000; 10: 475-8.
33. Cervoni N, Szyf M. Demethylase activity is directed by histone acetylation. J Biol Chem 2001; 276: 40778-87.
34. O'Neill RJW, Oneill MJ, Graves JAM. Undermethylation associated with retroelement activation and chromosome remodeling in an interspecific mammalian hybrid. Nature 1998; 393: 68-72.
35. Iguchi-Ariga SM, Schaffner W. CpG methylation of the cAMP-responsive enhacer/promotor sequence TGACGGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev 1989; 3: 612-19.
36. Tate PH, Bird AP. Effects of DN methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 1993; 3: 226-31.
37. Holler M, Westin G, Jiricny J, Schaffner W. Sp1 transcription factor binds DNA and activates transcription even when the binding site is CpG methylated. Genes Dev 1988; 2: 1127-35.
38. Meehan RR, Lewis JD, McKay S, Kleiner EL, Bird AP. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 1989; 58: 499-507.
39. Nan X, Meehan RR, Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res 1993; 21: 4886-92.
40. Meehan RR, Lewis JD, Bird AP. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res 1992; 20: 5085-92.
41. Wade PA. Methyl CpG-binding proteins and transcriptional repression. Bioessays 2001; 23: 1131-7.
42. Ballestar E, Wolffe AP. Methyl-CpG binding proteins. Eur J Biochem 2001; 268: 1-6.
43. Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 1999; 401: 301-4.
44. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a historic deacetylase complex. Nature 1998; 393: 386-9.
45. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG binding protein 2. Nat Genet 1999; 23: 185-8.
46. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature 1999; 397: 579-83.
47. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N. Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187-91.
48. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex couples DNA methylation to chromatin remodelling and historic deacetylation. Nat Genet 1999; 23: 62-6.
49. Wade P. Transcripcional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 2001; 10: 693-8.
50. Cervantes-Peredo A, López-López M. Bases moleculares de la herencia. En: Guízar Vázquez JJ. (ed.). Genética clínica. Diagnóstico y manejo de las enfermedades hereditarias. 3a. Ed. México, D.F.: Manual Moderno; 2001, p. 5-71.
51. Richards EJ, Elgin SCR. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 2002; 108: 489-500.
52. Jenuwein T, Allis CD. Translating the historic code. Science 2001; 293: 1074-80.
53. Rakyan VK, Preis J, Morgan HD, Whitelaw E. The marks, mechanism and memory of epigenetic states in mammals. Biochem J 2001; 356: 1-10.
54. Marmonstein R, Roth SY. Historic acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev 2001; 11: 155-61.
55. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 1999; 13: 1924-35.
56. Strahl BD, Ohba R, Cook RG, Allis CD. Methylation of histone H3 a1 lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc Natl Acad Sci USA 1999; 96: 14967-72.
57. Nakayama J, Rice JC, Strahl BD, Allis CD, Grewald SI. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 2001; 292: 110-3.
58. Bannister A, Schneider R, Kouzarides T. Historic methylation: dynamic or static? Cell 2002; 109: 801-6.
59. Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 2001; 414: 277-83.
60. Richards EJ. Chromatin methylation: who's on first? Curr Biol 2002; 12: R694-5.
61. Mermoud JE, Popova B, Peters AH, Jenuwein T, Brockdorff N. Historic H3 lysine 9 methylation occurs rapidly at the onset of random X chromosome inactivation. Curr Biol 2002; 12: 247-51.
62. Xin Z, Allis D, Wagstaff J. Parent-specific complementary patterns of histone H3 lysine 9 and H3 lysine 4 methylation at Prader-Willi syndrome imprinting center. Am J Hum Genet 2001; 69: 1389-94.
63. Brachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW, Vogelstein B. Histone modifications and silencing prior DNA methylation of a tumor suppressor gene. Cancer Cell 2003; 3: 89-95.
64. Nguyen CT, Weisenberg DJ, Velicescu M, Gonzales FA, Lin JCY, Liang G, Jones PA. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′ deoxycytidine. Cancer Res 2002; 62: 6456-61.
65. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002; 62: 7213-8.
66. Heard E, Clerc P, Avner P. X-chromosome inactivation in mammals. Annu Rev Genet 1997; 31: 571-610.
67. Kass SU, Landsberger N, Wolffe AP. DNA methylation directs a time-dependent repression of transcription initiation. Curr Biol 1997; 7: 157-65.
68. Brockdorff N. 2002. X-chromosome inactivation: closing in on proteins that bind Xist RNA. Trends Genet 18- 352-8.
69. Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tolorenzi R, Willard H. A gene from the region of the human X inactivation center is expressed exclusively from the inactive X chromosome. Nature 1991; 349: 38-44.
70. Panning B, Jaenisch R. DNA hipomethylation can activate Xist expression and silence X-linked genes. Genes Dev 1996; 10: 1991-2002.
71. Avner P, Heard E. X-chromosome inactivation: counting, choice and initiation. Nat Rev Genet 2001; 2: 59-67.
72. Boumil RM, Lee JT. Forty years of decoding the silence in X-chromosome inactivation. Hum Mol Genet 2001 10: 2225-32.
73. Gilbert SL, Sharp PA. Promotor-specific hypoacetylation of X inactivated genes. Proc Natl Acad Sci Usa 1999; 96: 13825-30.
74. Chadwick BP, Willard HF. Cell cycle-dependent localization of macro H2A in chromatin of the inactive X chromosome. J Cell Biol 2002; 157: 1113-23.
75. Lee JT, Davidow LS, Warshawsky D. Tsix, a gene antisense to Xist at the X-inactivation center. Nat Genet 1999; 21: 400-4.
76. Reik W, Walter J. Genomic Imprinting: parental influence on the genome. Nat Rev Genet 2001; 2: 21-32
77. Lopes S, Lewis A, Hajkova P, Dean W, Oswald J, Forné T, Murrell A, Constância M, Walter J, Reik W. Epigenetic modifications in an imprinting cluster are controlled by a hierarchy of DMRs suggesting long-range chromatin interactions. Hum Mol Genet 2003; 12: 295-305.
78. Tycko B, Morison IM. Physiological functions of imprinted genes. J Cell Physiol 2002; 192: 245-58.
79. Feinberg AP. The two-domain hypothesis in Beckwith-Wiedemann syndrome. J Clin Invest 2000; 106: 739-40.
80. Maher E, Reik W. Beckwith-Wiedemann syndrome: imprinting in cluster revisited. J Clin Invest 2000; 105: 247-52.
81. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 2000; 405: 482-5.
82. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000; 405: 486-9.
83. Szabo P, Tang SH, Rentsendorj A, Pfeifer GP, Mann JR. Maternal-specific footprints at putative CTCF sites in the H19 imprinting control region give evidence for insulator function. Curr Biol 2000; 10: 607-10.
84. Ferguson-Smith AC, Surani MA. Imprinting and the epigenetic asymmetry between parental genomes. Science 2001; 293: 1086-9.
85. Zwart R, Sleutels F, Wutz A, Schinkel AH, Barlow DP. Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes. Genes Devl 2001; 15: 2361-6.
86. Horike S, Mitsuya K, Meguro M, Kotobuki N, Kashiwagi A, Notsu T, Schulz TC, Shirayoshi Y, Oshimura M. Targeted disruption of the human LIT locus defines a putative imprinting control element playing an essential role in Beckwith-Wiedemann syndrome. Hum Mol Genet 2000; 9: 1829-41.
87. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet 2000; 1: 11-19.
88. Hendrick B, Bickmore W. Human disease with underlying defects in chromatin structure and modification. Hum Mol Genet 2001; 10: 2233-42.
89. Plass C. Cancer epigenomics. Hum Mol Genet 2002; 11: 2479-88.
90. Franceschini P, Martino S, Ciocchini M, Ciuti E, Vardeu MP, Guala A, Signorile F, Camerano P, Franceschini D, Tovo PA. Variability of clinical and immunological phenotype in immunodeficiency-centromeric instability-facial anomalies syndrome. Eur J Pediatr 1995; 154: 840-6.
91. Tao Q, Huang H, Geiman TM, Lim CY, Qiu GH, Robertson KD. Defective de novo methylation of viral and cellular sequences in ICF syndrome cells. Hum Mol Genet 2002; 11: 2091-102.
92. Xie S, Wang Z, Okano M, Nogami M, Li Y, He WW, Okumura K, Li E. Clonning, expression and chromosome locations of the human DNMT3 gene family. Gene 1999; 236: 87-95.
93. Dragich J, Houwink-Manville I, Schanen C. Rett syndrome: a surprising result of a mutation in MECP2. Hum Mol Genet 2000; 9: 2365-75.
94. Webb T, Latif F. Rett syndrome and the MECP2 gene. J Med Genet 2001; 38: 217-23.
95. Webb T, Watkiss E. A comparative study of X inactivation in Rett syndrome probands and control subjects. Clin Genet 1996; 49: 189-95.
96. Imessaoudene B, Bonnefont JP, Royer G, Cormier-Daire V, Lyonnet S, Iyon G, Munnich A, Amiel J. MECP2 mutation in non-fatal, non progressive encephalopathy in a male. J Med Genet 2001; 38: 171-4.
97. Ballestar E, Yuzufzai TM, Wolffe AP. Effects of rett syndrome mutations on the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA. Biochemistry 2000; 39: 7100-6.
98. Shahbazian MD, Zoghbi HY. Rett syndrome and MeCP2: linking epigenetics and neuronal function. Am J Hum Genet 2002; 71: 1259-72.
99. Orrico A, Lam CW, Galli L, Dotti MT, Hayek G, Tong SF, Poon PMK, Zapella M, Federico A, Sorrentino V. MECP2 mutation in male patients with non specific X-linked mental retardation. FEBS Lett 2000; 481: 285-8.
100. Picketts DJ, Higgs DR, Bachhoo S, Blake DJ, Quarrell OW, Gibbons RJ. ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome. Hum Mol Genet 1996; 5: 1899-907.
101. Gibbons RJ, Mc Dowell TL, Raman S, O'Rourke DM, Garrick D, Ayyub H, Higgs DR. Mutations in ATRX encoding a SWI/SNF-like protein cause diverse changes in the pattern of DNA methylation. Nat Genet 2000; 24: 368-71.
102. Turner G, Webb T, Wake S, Robinson H. The prevalence of the fragile X syndrome. Am J Med Genet 1996; 64: 196-7.
103. Oostra BA, Chiurazzi P. The fragile X Gene and its function. Clin Genet 2001; 60: 399-408.
104. Jin P, Warren ST. Undestanding the molecular basis of fragile X syndrome. Hum Mol Genet 2000; 9: 901-8.
105. Vertek AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65: 905-14.
106. Oberle I, Rosseau F, Heitz D, Kretz C, Devys D, Hanauer A, Boue J, Bertheas MF, Mandel JL. Inestability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 1991; 252: 1097-102.
107. Coffe B, Zhang F, Ceman S, Warren ST, Reines D. Histone modifications depict and aberrantly heterocromatinized FMR1 gene in fragile X syndrome. Am J Hum Genet 2002; 71: 923-32.
108. Mzroui R, Huot ME, Tremblay S, Filion C, Labelle Y, Khandjian W. Trapping of messenger RNA by the fragile X mental retardation protein into cytoplasmic granules induces translation repression. Hum Mol Genet 2002; 11: 3007-17.
109. De Baun MR, Niemitz EL, Mc Neil DE, Bradenburg SA, Lee MP, Freinberg AP. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am J Hum Genet 2002; 70: 604-11.
110. Mann MR, Bartolomei MS. Towards a molecular understanding of Prader-Willi and Angelman syndromes. Hum Mol Genet 1999; 8: 1867-73.
111. Gunay-Aygun M, Schwartz S, Heeger S, O'Riordan MA, Cassidy SB. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001; 108: 1-5
112. Nicholls RD, Saitoh S, Horsthemke B. Imprinting in Prader-Willi and Angelman syndromes. Trends Genet 1998; 14: 194-200.
113. Perk J, Makedonski K, Lande L, Cedar H, Razin A, Shemer R. The imprinting mechanism of the Prader-Willi/Angelman regional control center. EMBO J 2002; 21: 5807-14.
114. Buiting K, Grob S, Lich C, Gillessen-Kaesbach G, El-Maari O, Horsthemke B. Epimutations in Prader-Willi and Angelman syndromes: a molecular study of 136 patients with imprinting defect. Am J Hum Genet 2003; 72: 571-7.
115. Cox GF, Bürger J, Lip V, Ulrike A, Mau UA, Sperling K, Wu BL, Horsthemke B. Intracytoplasmatic sperm injection may increase the risk of imprinting defects. Am J Hum Genet 2002; 71: 162-4.
116. Óstavik KH, Eiklid K, Ven Der Hagen CB, Spetalen S, Kierulf K, Skejeldal O, Buiting K. Another case of imprinting defect in a girl with Angelman syndrome who was conceived by intracytoplasmic sperm injection. Am J Hum Genet 2003; 72: 218-9.
117. DeBaun MR, Niemitz EL, Feinberg AP. Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am J Hum Genet 2003; 72: 156-60.
118. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
119. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 2002; 111: 115-27.